Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26673570
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Synthetic biology for pharmaceutical drug discovery
#MMPMID26673570
Trosset JY
; Carbonell P
Drug Des Devel Ther
2015[]; 9
(?): 6285-302
PMID26673570
show ga
Synthetic biology (SB) is an emerging discipline, which is slowly reorienting the
field of drug discovery. For thousands of years, living organisms such as plants
were the major source of human medicines. The difficulty in resynthesizing
natural products, however, often turned pharmaceutical industries away from this
rich source for human medicine. More recently, progress on transformation through
genetic manipulation of biosynthetic units in microorganisms has opened the
possibility of in-depth exploration of the large chemical space of natural
products derivatives. Success of SB in drug synthesis culminated with the
bioproduction of artemisinin by microorganisms, a tour de force in protein and
metabolic engineering. Today, synthetic cells are not only used as biofactories
but also used as cell-based screening platforms for both target-based and
phenotypic-based approaches. Engineered genetic circuits in synthetic cells are
also used to decipher disease mechanisms or drug mechanism of actions and to
study cell-cell communication within bacteria consortia. This review presents
latest developments of SB in the field of drug discovery, including some
challenging issues such as drug resistance and drug toxicity.
free
free
free
